所有图片（1/1）
分享产品介绍 评论(0)
产品规格
宿主来源
Human抗原名称
PD-L1分子别名
Programmed cell death 1 ligand 1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1Accession
Q9NZQ7克隆号
S-SC015抗体类型
Recombinant mAb抗体同种型
IgG1,k纯化方式
Protein A浓度
2 mg/ml内毒素含量
<1EU/mg标记
Unconjugated性状
Liquid缓冲体系
PBS pH7.4, containing no preservative储存条件
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用
Blocking of PD-1/PD-L1 signaling Functional assays稀释度
应用 稀释度 ELISA 1.221-5000 ng/ml
背景介绍
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma. It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
ELISA
Immobilized human PD-L1 at 0.5 μg/ml (50 μL/well) can bind to Atezolizumab with a linear range of 1.221 ng/ml-5 μg/ml.
评论(0)